Ionophore Toxin Maduramicin Produces Haff Disease-Like Rhabdomyolysis in a Mouse Model

Maduramicin ammonium impairs autophagic flux through activating AMPK-mediated eIF2α-ATF4 endoplasmic reticulum stress pathway in skeletal muscle

BACKGROUND

Maduramicin ammonium (MA), a widely used coccidiostat, has been reported to cause skeletal muscle degeneration in animals and even humans. In this study, we explore the underlying mechanism of its toxicity in skeletal muscle.

RESULTS

First, we observed that MA impaired autophagic flux which was evidenced by increased protein level of LC3-II and p62 in skeletal myoblast C2C12 and L6 cell lines and rectus femoris muscle tissues of rats and broilers. Then, we found that MA induced eIF2α phosphorylation and ATF4 expression in the cells and tissues. Co-treatment with ISRIB attenuated MA-induced LC3-II and p62 in C2C12 and L6 cells, suggesting that MA-induced eIF2α-ATF4 pathway contributed to impairment of autophagic flux in the cells. Lastly, we showed that MA activated AMPK signaling in skeletal muscle, since the phosphorylation of AMPK was increased by MA treatment in skeletal myoblast cell lines and muscle tissues. Furthermore, in AMPK downregulated C2C12 cells, MA-induced LC3-II, ATF4 and phosphorylation of eIF2α was reversed, supporting that AMPK was involved in the regulation of the eIF2α-ATF4 pathway and autophagic flux during MA exposure.

CONCLUSION

Our findings showed that MA impairs autophagic flux through activating the AMPK-induced eIF2α-ATF4 pathway in skeletal muscle. © 2024 Society of Chemical Industry.

Outbreak of Haff disease caused by crayfish in China: a systematic review

BACKGROUND

Haff disease is a condition that has emerged in China in recent years, primarily associated with the consumption of crayfish. Despite its increasing incidence, the exact cause of Haff disease remains unknown, prompting further investigation into its potential triggers and risk factors. The purpose of this system review is to investigate and summarize the current understanding of Haff disease and provide insights into the etiology and pathogenesis of Haff disease by collecting and analyzing data from a large number of patients.

METHOD

Systematic searches were conducted in PubMed, CNKI, and Wanfang Databases to investigate and summarize Haff disease by crayfish consumption in China over recent years. The search included observational studies published up to May 1, 2024.

RESULT

This review collected data from 1437 patients and conducted a comprehensive analysis of symptoms. In-depth examinations of patient symptoms revealed that nearly all patients exhibited abnormally elevated serum creatine kinase levels and muscular pain, while some also experienced changes in urine color, abdominal discomfort, and chest pain. Risk factors associated with Haff disease from crayfish consumption included high crayfish consumption, alcohol use, the consumption of specific crayfish organs such as the head, liver, and pancreas, and the consumption of wild crayfish.

CONCLUSION

Haff disease is indeed related to the consumption of crayfish, which may be due to the presence of an unknown heat stable toxin in crayfish. During the research process, many risk factors were identified, and it is recommended that people who consume crayfish pay attention to these risk factors and take appropriate preventive measures to minimize the risk of illness.

Maduramicin-guided nanotherapy: A polymeric micelles for targeted drug delivery in canine mammary tumors

Canine mammary tumors (CMT) can severely compromise the life quality of the affected dogs through local recurrence, distant metastases and ultimately succumb to death. Recently, more attention has been given to the potential antimetastatic effect of maduramicin (MAD) on breast cancer. However, its poor aqueous solubility and toxicity to normal tissues limit its clinical application. Therefore, to address the drawbacks of MAD and enhance its anticancer and antimetastatic effects, MAD-loaded TPGS polymeric micelles (MAD-TPGS) were prepared by a thin-film hydration technique. The optimized MAD-TPGS exhibited excellent size distribution, stability and improved water solubility. Cellular uptake assays showed that TPGS polymer micelles could enhance drug internalization. Moreover, TPGS synergistically improved the cytotoxicity of MAD by targeting mitochondrial organelles, improving reactive oxygen species levels and reducing the mitochondrial transmembrane potential. More importantly, MAD-TPGS significantly impeded the metastasis of tumor cells. In vivo results further confirmed that, in addition to exhibiting excellent biocompatibility, MAD-TPGS exhibited greater antitumor efficacy than free MAD. Interestingly, MAD-TPGS displayed superior suppression of CMT metastasis via tail vein injection compared to oral administration, indicating its suitability for intravenous delivery. Overall, MAD-TPGS could be applied as a potential antimetastatic cancer agent for CMT.

Repurposing maduramicin as a novel anticancer and anti-metastasis agent for triple-negative breast cancer as enhanced by nanoemulsion

Triple-negative breast cancer (TNBC) is featured by aggression and metastasis and remains an unmet medical challenge due to high death rate. We aimed to repurpose maduramicin (MAD) as an effective drug against TNBC, and develop a nanoemulsion system to enhance anticancer efficacy of MAD. MDA-MB-231 and 4 T1 cells were used as in vitro model, and cell viability was determined by performing cell counting kit-8 and a colony-formation assay. Furthermore, MAD loaded nanoemulsion (MAD-NEs) was manufactured and characterized by a series of tests. The anticancer and anti-metastasis mechanism of MAD-NEs were assessed by performing cell cycle, apoptosis, wound-healing, transwell assay and Western blotting assays. Herein, MAD was firstly demonstrated to be an effective agent to suppress growth of TNBC cells. Subsequently, the optimized MAD-NEs were shown to have stability and high encapsulation efficiency, and could arrested cells in G0/G1 phase and induced apoptosis in TNBC cells. More importantly, MAD-NEs significantly impeded the metastasis of tumor cells, which was further demonstrated by the significant altered expression of epithelial-mesenchymal transition and extracellular matrix markers in vitro and in vivo. Moreover, compared to MAD, MAD-NEs exhibited higher efficacy in shrinking breast tumor size and repressing liver and lung metastasis in vivo, and showed excellent biocompatibility in tumor-bearing mice. The successfully prepared MAD-NEs are expected to be harnessed to suppress tumor growth, invasion and metastasis in the battle against malignant TNBC.

Effect of maduramicin on crayfish (Procambius clarkii): Hematological parameters, oxidative stress, histopathological changes and stress response

Maduramicin, an extensively used anticoccidial drug, has been introduced into environment due to poorly absorbed in the intestine of broiler chicken. To understand the potential ecological toxicity of maduramicin on aquatic organisms, acute and subacute toxicity, hemolymph biochemistry, histopathology and the expressions of drug metabolism and stress response genes of crayfish (Procambius clarkii) were investigated in this study. For the first time, the 96 h median lethal concentration (LC₅₀) of maduramicin on crayfish was 67.03 mgL^-1 with a 95% confidence interval (54.06-81.32 mgL^-1). Then, the crayfish were exposed to 0.7 mgL^-1 (1/100 LC₅₀), 3.5 mgL^-1 (1/20 LC₅₀) and 7.0 mgL^-1 (1/10 LC₅₀) maduramicin for 28 days. Maduramicin significantly altered biochemical parameters including AST, ALT, CK, LDH and ALP of hemolymph in crayfish at several time points. The activities of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx) of crayfish gills, hepatopancreas and abdominal muscle were significantly decreased or elevated by different concentrations of maduramicin treatment at varying time points. Furthermore, histopathological damage of crayfish gills, hepatopancreas and abdominal muscle were observed in a concentration-dependent manner. The expressions of metabolic and stress response genes (CYP450, GST, COX1, COX2, HSP70 and MT) in hepatopancreas of crayfish were significantly up-regulated by maduramicin (7.0 mgL^-1) treatment for 8 h to 7 d, and returned to normal levels after the removal of maduramicin for 3-7 days. In conclusion, our findings demonstrated that environmental exposure of maduramicin threaten to the health of crayfish living in the areas nearby livestock farms or pharmaceutical factory. Crayfish exhibited resistance to the stress of maduramicin via activating drug metabolite and detoxification pathways.